phrykt

Corcept Therapeutics Inc (CORT): who owns it and who trades it

As of Nov 16, 2026, CORT insiders reported 107 open-market sales worth $97.7M and 2 purchases worth $3.3M in the last 12 months, with 9% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sean Maduck (See Remarks), with $25M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Corcept Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CORT

420 funds and institutions reported CORT shares worth $7.2B at the end of Q2 2026, about 78% of the company. The largest holder is BlackRock, Inc. with 11.6%.

Funds and institutions (13F) 78%Everyone else 22%

10 largest owners, by share of the company

BlackRock, Inc.11.6%
Ingalls & Snyder LLC7.4%
Renaissance Technologies LLC4.9%
Vanguard Portfolio Management LLC4.7%
Vanguard Capital Management LLC3.9%
Parallel Advisors, LLC3.7%
FMR LLC (Fidelity)3.1%
State Street Corp3.1%
AQR Capital Management LLC2.4%
Geode Capital Management, LLC2.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.12.43M11.58%$1.1B+2%
Ingalls & Snyder LLC7.93M7.39%$690M+4%
Renaissance Technologies LLC5.26M4.90%$457M-7%
Vanguard Portfolio Management LLC5.04M4.70%$439M+5%
Vanguard Capital Management LLC4.17M3.89%$363M+2%
Parallel Advisors, LLC3.96M3.69%$345M-0%
FMR LLC (Fidelity)3.34M3.11%$290M+5%
State Street Corp3.28M3.05%$285M+2%
AQR Capital Management LLC2.58M2.41%$225M+536%
Geode Capital Management, LLC2.53M2.36%$220M-7%
First Trust Advisors LP1.83M1.70%$159M-16%
Tang Capital Management LLC1.50M1.40%$130MNo change
UBS Group AG1.38M1.28%$120M+1%
Dimensional Fund Advisors LP1.32M1.23%$115M-15%
Charles Schwab Investment Management Inc1.16M1.08%$101M+3%
Sixth Street Partners Management Company, L.P.1.16M1.08%$101M–
Morgan Stanley1.14M1.06%$98.9M+12%
D. E. Shaw & Co., Inc.883,0010.82%$76.8M-25%
Cerity Partners LLC797,1190.74%$69.3M+9%
Mpm Bioimpact LLC771,0280.72%$67M-22%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CORT insiders reported $3.3M of open-market purchases and $97.7M of sales. 9% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$3.3M
2 trades, 1 people
Sales, 12 months
$97.7M
107 trades, 11 people
Sales under a 10b5-1 plan
9%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 13, 2026

Purchases and sales by month

$27M$27MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026Daniel N Swisher JRDirectorSale plan1,500$74.07$111KForm 4
Nov 3, 2026Sean MaduckOtherSale plan8,617$82.02$707KForm 4
Nov 3, 2026Sean MaduckOtherSale plan4,542$82.68$376KForm 4
Nov 2, 2026Roberto Wandenkolk VieiraPresidentSale plan6,657$80.73$537KForm 4
Nov 2, 2026Roberto Wandenkolk VieiraPresidentSale plan1,676$81.52$137KForm 4
Nov 2, 2026Sean MaduckOtherSale plan11,841$81.42$964KForm 4
Oct 15, 2026James N WilsonDirectorSale plan6,654$114.48$762KForm 4
Oct 15, 2026James N WilsonDirectorSale plan3,046$115.39$351KForm 4
Oct 15, 2026James N WilsonDirectorSale plan300$116.30$34.9KForm 4
Oct 2, 2026Sean MaduckSee RemarksSale plan15,843$116.12$1.8MForm 4
Oct 2, 2026Sean MaduckSee RemarksSale plan8,744$116.55$1MForm 4
Oct 2, 2026Joseph Douglas LyonSee RemarksSale plan4,446$115.70$514KForm 4
Oct 2, 2026Joseph Douglas LyonSee RemarksSale plan4,744$116.54$553KForm 4
Oct 2, 2026Roberto Wandenkolk VieiraPresidentSale plan1,100$114.52$126KForm 4
Oct 2, 2026Roberto Wandenkolk VieiraPresidentSale plan2,086$115.73$241KForm 4
Oct 2, 2026Roberto Wandenkolk VieiraPresidentSale plan5,147$116.58$600KForm 4
Oct 1, 2026Sean MaduckSee RemarksSale plan413$115.54$47.7KForm 4
Oct 1, 2026Joseph Douglas LyonSee RemarksSale plan810$115.40$93.5KForm 4
Sep 16, 2026Roberto Wandenkolk VieiraPresidentSale296$100.82$29.8KForm 4
Sep 15, 2026James N WilsonDirectorSale2,800$111.70$313KForm 4
Sep 15, 2026James N WilsonDirectorSale400$110.84$44.3KForm 4
Sep 15, 2026James N WilsonDirectorSale6,800$110.27$750KForm 4
Sep 14, 2026Joseph Douglas LyonSee RemarksSale7,812$113.32$885KForm 4
Sep 14, 2026Joseph Douglas LyonSee RemarksSale2,188$114.12$250KForm 4
Sep 2, 2026Roberto Wandenkolk VieiraPresidentSale1,225$115.44$141KForm 4
Sep 2, 2026Roberto Wandenkolk VieiraPresidentSale5,621$114.58$644KForm 4
Sep 2, 2026Roberto Wandenkolk VieiraPresidentSale1,606$113.72$183KForm 4
Sep 2, 2026Roberto Wandenkolk VieiraPresidentSale1,537$111.37$171KForm 4
Sep 2, 2026Roberto Wandenkolk VieiraPresidentSale23,770$110.70$2.6MForm 4
Sep 2, 2026Roberto Wandenkolk VieiraPresidentSale23,600$109.35$2.6MForm 4
Sep 2, 2026Roberto Wandenkolk VieiraPresidentSale974$112.40$109KForm 4
Sep 1, 2026Sean MaduckSee RemarksSale11,730$113.94$1.3MForm 4
Sep 1, 2026Sean MaduckSee RemarksSale2,281$115.61$264KForm 4
Sep 1, 2026Sean MaduckSee RemarksSale10,989$114.71$1.3MForm 4
Aug 26, 2026Kimberly ParkDirectorSale26,685$122.55$3.3MForm 4
Aug 25, 2026Sean MaduckSee RemarksSale5,870$126.06$740KForm 4
Aug 25, 2026Sean MaduckSee RemarksSale25,085$125.47$3.1MForm 4
Aug 18, 2026David L MahoneyDirectorSale91,167$118.24$10.8MForm 4
Aug 18, 2026David L MahoneyDirectorSale400$119.64$47.9KForm 4
Aug 18, 2026David L MahoneyDirectorSale7,055$118.88$839KForm 4
Aug 18, 2026David L MahoneyDirectorSale4,984$117.47$585KForm 4
Aug 17, 2026Gary Charles RobbChief Business OfficerSale10,000$116.26$1.2MForm 4
Aug 14, 2026Sean MaduckSee RemarksSale3,664$114.49$419KForm 4
Aug 14, 2026James N WilsonDirectorSale3,053$110.49$337KForm 4
Aug 14, 2026James N WilsonDirectorSale2,279$112.64$257KForm 4
Aug 14, 2026James N WilsonDirectorSale4,668$111.44$520KForm 4
Aug 10, 2026Sean MaduckSee RemarksSale1,031$114.52$118KForm 4
Aug 10, 2026William GuyerChief Development OfficeSale11,530$113.18$1.3MForm 4
Aug 10, 2026William GuyerChief Development OfficeSale4,770$114.04$544KForm 4
Aug 4, 2026William GuyerChief Development OfficeSale3,700$113.12$419KForm 4
Aug 3, 2026Sean MaduckSee RemarksSale20,305$114.70$2.3MForm 4
Aug 3, 2026Joseph Douglas LyonSee RemarksSale1,540$114.16$176KForm 4
Jul 30, 2026Atabak MokariCFOSale7,089$116.96$829KForm 4
Jul 30, 2026Atabak MokariCFOSale8,267$117.93$975KForm 4
Jul 30, 2026Atabak MokariCFOSale4,783$118.73$568KForm 4
Jul 30, 2026Atabak MokariCFOSale8,103$119.95$972KForm 4
Jul 30, 2026Atabak MokariCFOSale1,001$120.67$121KForm 4
Jul 30, 2026Atabak MokariCFOSale8,956$106.96$958KForm 4
Jul 30, 2026Atabak MokariCFOSale400$108.46$43.4KForm 4
Jul 30, 2026Atabak MokariCFOSale2,202$110.03$242KForm 4
Jul 30, 2026Atabak MokariCFOSale600$110.95$66.6KForm 4
Jul 30, 2026Atabak MokariCFOSale4,700$113.18$532KForm 4
Jul 30, 2026Atabak MokariCFOSale15,477$114.96$1.8MForm 4
Jul 30, 2026Atabak MokariCFOSale14,222$115.87$1.6MForm 4
Jul 30, 2026Atabak MokariCFOSale4,200$105.54$443KForm 4
Jul 15, 2026James N WilsonDirectorSale1,079$86.78$93.6KForm 4
Jul 15, 2026James N WilsonDirectorSale3,969$87.74$348KForm 4
Jul 15, 2026James N WilsonDirectorSale1,978$89.49$177KForm 4
Jul 15, 2026James N WilsonDirectorSale2,974$88.81$264KForm 4
Jul 15, 2026Atabak MokariCFOSale101$89.43$9KForm 4
Jul 15, 2026Atabak MokariCFOSale3,520$88.30$311KForm 4
Jul 15, 2026Atabak MokariCFOSale28,460$87.89$2.5MForm 4
Jul 15, 2026Atabak MokariCFOSale7,919$86.78$687KForm 4
Jul 7, 2026William GuyerChief Development OfficeSale19,048$93.11$1.8MForm 4
Jul 7, 2026William GuyerChief Development OfficeSale952$93.54$89.1KForm 4
Jul 1, 2026Sean MaduckSee RemarksSale11,024$87.33$963KForm 4
Jul 1, 2026Sean MaduckSee RemarksSale2,801$88.51$248KForm 4
Jul 1, 2026Sean MaduckSee RemarksSale11,175$89.31$998KForm 4
Jun 17, 2026David L MahoneyDirectorSale20,000$84.53$1.7MForm 4
Jun 16, 2026James N WilsonDirectorSale4,177$82.69$345KForm 4
Jun 16, 2026James N WilsonDirectorSale5,823$83.57$487KForm 4
Jun 15, 2026Atabak MokariCFOSale2$82.45$165Form 4
Jun 15, 2026Atabak MokariCFOSale9,434$80.02$755KForm 4
Jun 15, 2026Atabak MokariCFOSale11,081$80.94$897KForm 4
Jun 15, 2026Atabak MokariCFOSale19,483$81.81$1.6MForm 4
Jun 2, 2026William GuyerChief Development OfficeSale20,000$70.60$1.4MForm 4
Jun 1, 2026Sean MaduckSee RemarksSale21,069$70.11$1.5MForm 4
Jun 1, 2026Sean MaduckSee RemarksSale3,931$70.75$278KForm 4
Jun 1, 2026Atabak MokariCFOSale40,000$70.00$2.8MForm 4
Jun 1, 2026Joseph K BelanoffCEOSale12,837$69.74$895KForm 4
May 27, 2026Joseph Douglas LyonSee RemarksSale5,000$65.00$325KForm 4
May 27, 2026Sean MaduckSee RemarksSale54,575$65.37$3.6MForm 4
May 27, 2026Sean MaduckSee RemarksSale20,425$66.16$1.4MForm 4
May 5, 2026William GuyerChief Development OfficeSale20,000$51.83$1MForm 4
May 1, 2026Joseph K BelanoffCEOSale40,000$50.10$2MForm 4
Apr 7, 2026William GuyerChief Development OfficeSale20,000$40.97$819KForm 4
Mar 25, 2026Joseph K BelanoffCEOSale26,198$50.07$1.3MForm 4
Mar 20, 2026William GuyerChief Development OfficeSale11,767$36.01$424KForm 4
Mar 17, 2026G Leonard Baker JrDirectorPurchase24,218$33.56$813KForm 4
Mar 17, 2026G Leonard Baker JrDirectorPurchase75,782$33.00$2.5MForm 4

Latest 100 of 109 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Sean MaduckSee Remarks–$25MNov 3, 2026
Atabak MokariChief Financial Officer–$18.7MJul 30, 2026
David L MahoneyDirector–$13.9MAug 18, 2026
William GuyerChief Development Officer–$11.6MAug 10, 2026
Roberto Wandenkolk VieiraPresident, Oncology–$8.1MNov 2, 2026
Joseph K BelanoffChief Executive Officer, Director–$7.4MJun 1, 2026
James N WilsonDirector–$5.1MOct 15, 2026
G Leonard Baker JrDirector$3.3M–Mar 17, 2026
Kimberly ParkDirector–$3.3MAug 26, 2026
Joseph Douglas LyonSee Remarks–$3.2MOct 2, 2026
Gary Charles RobbChief Business Officer–$1.2MAug 17, 2026
Daniel N Swisher JRDirector–$111KNov 10, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CORT short interest

Moderate short interest. 8.3% of CORT shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 2%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.13M CORT shares were sold short, 8.3% of the shares outstanding, up 6.3% from the report before. At the average daily volume of 1.13M shares, buying them all back would take about 8.1 trading days (days to cover).

Shares short, % of all shares

8.34%May 15Oct 309.26%

Days to cover

8.1May 15Oct 3013.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.13M8.34%+6%1.13M8.1
Oct 15, 20268.59M7.95%+1%698,64412.3
Sep 30, 20268.54M7.90%-9%2.39M3.6
Sep 15, 20269.35M8.65%-1%944,0429.9
Aug 31, 20269.40M8.69%-3%789,53811.9
Aug 14, 20269.70M8.97%-1%927,93110.4
Jul 31, 20269.82M9.08%+4%1.54M6.4
Jul 15, 20269.44M8.80%+9%1.09M8.7
Jun 30, 20268.64M8.05%+1%1.03M8.4
Jun 15, 20268.57M7.98%-3%969,2608.8
May 29, 20268.79M8.19%-6%1.03M8.6
May 15, 20269.32M8.68%-13%1.48M6.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Corcept Therapeutics company events

Corcept Therapeutics filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Sep 23, 2026LeadershipSean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated of his decision to resign effective as of October 1, 2026. Filing
  3. Jul 29, 2026ResultsReleased financial results. Filing
  4. Jun 17, 2026AnnouncementCorcept Therapeutics Incorporated issued a press release announcing that the Company has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing’s syndrome. Filing
  5. Jun 3, 2026AnnouncementCorcept Therapeutics Incorporated learned that the United States Department of Justice had filed a Notice of Election to Decline Intervention in a civil qui tam action filed against the company, captioned U.S. et al. ex rel. Filing
  6. May 28, 2026LeadershipCorcept Therapeutics Incorporated held its 2026 Annual Meeting of Stockholders. Filing
  7. Apr 30, 2026ResultsReleased financial results. Filing
  8. Mar 25, 2026AnnouncementCorcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has approved Lifyorli ™ (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal… Filing
  9. Feb 24, 2026ResultsReleased financial results. Filing
  10. Feb 19, 2026AnnouncementCorcept Therapeutics Incorporated issued a press release announcing that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym ® does not infringe two of the Company’s patents concerning methods of safely… Filing
  11. Jan 22, 2026AnnouncementCorcept Therapeutics Incorporated issued a press release announcing that ROSELLA, the Company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint. Filing
  12. Dec 31, 2025AnnouncementCorcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Corcept Therapeutics financials

Famous investors that hold CORT

6 of the 50 well-known investors we track reported holding CORT in their latest 13F filing. The largest position is Jim Simons's, worth $559M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20264.85M$559M0.8%-8%
Ray Dalio · Bridgewater AssociatesQ3 2026268,180$30.9M0.1%+366%
Ken Griffin · Citadel AdvisorsQ3 2026239,818$27.6M0.0%+120%
Israel Englander · Millennium ManagementQ3 2026152,576$17.6M0.0%No change
Paul Tudor Jones · Tudor Investment CorpQ3 202621,293$2.5M0.0%New
Larry Robbins · Glenview Capital ManagementQ3 20264,800$553K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CORT in the last 120 days.

FiledHolderFormStake
Oct 27, 2026BlackRock, Inc.13G/A8.9%
Oct 27, 2026BlackRock, Inc.13G/A8.9%

Questions about Corcept Therapeutics Inc (CORT) stock

Who owns the most CORT stock?

The largest reported owner of Corcept Therapeutics Inc (CORT) is BlackRock, Inc., with 11.6% of the company. In total, 420 funds and institutions reported holding CORT at the end of Q2 2026, together about 78% of the shares. See the largest owners.

Are CORT insiders buying or selling?

In the last 12 months, CORT insiders reported 2 open-market purchases worth $3.3M and 107 sales worth $97.7M. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in CORT?

As of Oct 30, 2026, 9.13M CORT shares were sold short, 8.3% of the shares outstanding, up 6.3% from the report before. At the average daily volume of 1.13M shares, buying them all back would take about 8.1 trading days (days to cover). See the history.

Which famous investors hold CORT?

6 of the 50 well-known investors we track reported CORT in their latest 13F filing, including Jim Simons, Ray Dalio, Ken Griffin. The largest position is worth $559M. See all holders.

Executive pay

Corcept Therapeutics's chief executive was paid a total of $15.3M for the year ended Dec 31, 2025, up 55% from $9.9M the year before. In the last 12 months, Corcept Therapeutics's executives and directors bought $3.3M of stock on the open market and sold $97.7M.

Chief executive, total pay$15.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$14.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$6.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.